|8:00 AM - 9:00 AM||
Breakfast & Analyst One-to-One Meetings
Moving AI Tools out of the "Science of AI" to Tools that Impact "Pharma Science"
|9:00 AM - 9:25 AM||
Breaking through the Bottleneck: A multi-omics Perspective on How Best to Use Data
How to best use data seems simple and straightforward, but in reality it is complicated and ambiguous. This high-powered session will cover how to best generate, evaluate and translate biomedical data into drug targets that lead to transformational, safe and effective medicines.
|9:25 AM - 9:55 AM||
Data is the New Key Asset: An Interactive Discussion with CDOs
This session puts a spotlight on the challenges all organizations are facing, but that are particularly prevalent in healthcare organizations. Join the conversation and help to facilitate and encourage change. We hope by the end of this discussion you will be able to commit to 1-2 things that you can influence in your role over the next year to make progress in more effective management of your data. Discussion points include:
|9:55 AM - 10:20 AM||
Real-World Evidence and AI: Where are We Now and How Can We Take the Next Steps Forward to Directly Impact Care?
This session will focus on the kind of real world data that is needed to realize the potential of AI. With so much opportunity for progress, prioritizing projects is a critical step in delivering on results. Speakers will help identify what types of questions are easier to answer and which are harder in order to help you choose the projects that will result in near term ROI. Using case study examples from two therapeutic areas, discussion will cover these questions and more:
|10:20 AM - 10:50 AM||
Morning Refreshments & Analyst One-to-One Meetings
|10:50 AM - 11:15 AM||
The Power of GANs and RL in pharma R&D: from Experimentally-Validated End-to-End Drug Discovery Pipelines to Generation of Synthetic Patients
GANs and GAN-RL systems are powerful tool for a plethora of drug discovery and biomarker development applications. The application of GANs for small molecule generation was pioneered by the scientists at Insilico Medicine with the first peer-reviewed paper titled "The cornucopia of meaningful leads" followed by series of the theoretical and experimental research papers. This session will cover usage of GAN’s by biopharmaceutical companies for:
|11:15 AM - 11:45 AM||
How do you Build/Modify your Organization around Data Strategy – Know what questions to ASK!
|11:45 AM - 12:00 PM||
Chair's Closing Remarks